Pablo J. Cagnoni Ph.D., M.D.
Net Worth
Last updated:
What is Pablo J. Cagnoni Ph.D., M.D. net worth?
The estimated net worth of Dr. Pablo J. Cagnoni Ph.D., M.D. is at least $5,104,034 as of 1 Feb 2023. He owns shares worth $5,941 as insider, has earned $48,093 from insider trading and has received compensation worth at least $5,050,000 in Rubius Therapeutics, Inc..
What is the salary of Pablo J. Cagnoni Ph.D., M.D.?
Dr. Pablo J. Cagnoni Ph.D., M.D. salary is $1,010,000 per year as Chief Executive Officer, Pres & Director in Rubius Therapeutics, Inc..
How old is Pablo J. Cagnoni Ph.D., M.D.?
Dr. Pablo J. Cagnoni Ph.D., M.D. is 62 years old, born in 1963.
What stocks does Pablo J. Cagnoni Ph.D., M.D. currently own?
As insider, Dr. Pablo J. Cagnoni Ph.D., M.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Rubius Therapeutics, Inc. (RUBY) | Chief Executive Officer, Pres & Director | 66,082 | $0.09 | $5,941 |
What does Rubius Therapeutics, Inc. do?
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Pablo J. Cagnoni Ph.D., M.D. insider trading
Rubius Therapeutics, Inc.
Dr. Pablo J. Cagnoni Ph.D., M.D. has made 3 insider trades between 2020-2023, according to the Form 4 filled with the SEC. Most recently he sold 8,448 units of RUBY stock worth $2,112 on 1 Feb 2023.
The largest trade he's ever made was exercising 25,000 units of RUBY stock on 31 Jan 2023. As of 1 Feb 2023 he still owns at least 66,082 units of RUBY stock.
Rubius Therapeutics key executives
Rubius Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Pablo J. Cagnoni Ph.D., M.D. (62) Chief Executive Officer, Pres & Director
- Mr. David R. Epstein B.Sc., M.B.A. (63) Executive Chairman
- Mr. Laurence A. Turka M.D. (67) Chief Scientific Officer and Head of Research & Translational Medicine